CVX vs PFE: Which Is the Better Buy?
Side-by-side comparison of Chevron Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-09.
Chevron Corporation · Energy
$175.91
-3.4% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CVX |
PFE |
| Current Price |
$175.91 |
$25.22 |
| Fair Value Estimate |
$169.96 |
$25.92 |
| Upside to Fair Value |
-3.4%
|
+2.8%
|
| Market Cap |
$350.3B |
$143.7B |
| Forward P/E |
30.4x
|
19.2x
|
| EV / EBITDA |
9.4x
|
12.3x
|
| Price / Sales |
1.9x
|
2.3x
|
| Price / FCF |
26.2x
|
15.2x
|
| Revenue Growth YoY |
+3.2%
|
+5.4%
|
| Gross Margin |
25.4%
|
69.3%
|
| Operating Margin |
8.4%
|
23.4%
|
| Return on Equity |
6.2%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.82%
|
6.6%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Chevron Corporation operates as a leading integrated oil and gas company within the energy sector, demonstrating medium business quality with a stable competitive position but facing earnings pressure as evidenced by a 36.9% decline in earnings in the most recent quarter. The stock trades at a premium valuation with a P/E trailing and forward of 30.38, EV/EBITDA of 9.41, and a P/FCF of 26.2, refl…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
CVX |
PFE |
| Zone Low |
$127.47 |
$19.44 |
| Zone High |
$144.47 |
$22.03 |
| In Buy Zone? |
No
|
No
|